1 (Image 1)
Duloxetine Capsule, Delayed Release Pellets
Product Images NDC 63629-8748
View Photos of Packaging, Regulatory Labels, and Product Appearance
Product Visual Gallery
This gallery contains 14 technical images submitted to the FDA as part of the official labeling for Duloxetine (NDC 63629-8748). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.
As provided by Bryant Ranch Prepack, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.
Figure6 (Image 10)
Figure8 (Image 11)
The text provides data on the percentage of patients improved using Placebo and Duloxetine Delayed-Release 60/120 mg Once Daily. It also includes a graph displaying the percentage improvement in pain from Baseline using Duloxetine Delayed-Release 60/120 mg Once Daily.*
Figure9 (Image 12)
This is a chart that displays the percentage of patients improved in terms of pain based on the baseline (BOCF) through the use of either a placebo or Duloxetine Delayed-Release 60 mg Once Daily medication. The chart indicates a gradual increase in pain relief as the percentage of patients improved rises from 0 to 100.*
Figure10 (Image 13)
1 (Image 2)
1 (Image 3)
1 (Image 4)
Figure1 (Image 5)
The text describes a graph showing the proportion of patients who experienced relapse over time from randomization, with different treatment groups indicated. The treatments represented are placebo, Dulorine and Rl Gapeis.*
Figure2 (Image 6)
The text describes a graph displaying the proportion of patients who experienced a relapse over time from randomization. There are two groups being compared, one taking a placebo and the other taking Duloxetine Delayed-Release Capsules. The graph was likely created using the Kaplan-Meier method.*
Figure3 (Image 7)
This text provides information on the percentage of patients who have shown improvement and the level of improvement in pain from the baseline. It does not provide any further details or context.*
Figure4 (Image 8)
Figure5 (Image 9)
The text describes a chart showing the percentage of patients who have seen improvement in their pain levels after taking either Duloxetine 60mg twice daily, Duloxetine 60mg once daily, or a placebo. Unfortunately, there is no information on the actual percentages or any other details of the chart.*
Label (Lbl636298748)
This is a medication description for Duloxetine Delayed-Release Capsules, USP. Each capsule contains 67.3 mg of duloxetine hydrochloride, USP equivalent to 60 mg duloxetine. It is important to keep the medication out of the reach of children and store it in a tight, light-resistant container with a child-resistant closure at controlled room temperature. The medication comes in a package of 30 capsules and is dispensed with a prescription.*
* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.
